SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-056933
Filing Date
2024-05-09
Accepted
2024-05-09 16:09:12
Documents
88
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fdmt-20240331.htm   iXBRL 10-Q 2338166
2 EX-31.1 fdmt-ex31_1.htm EX-31.1 19005
3 EX-31.2 fdmt-ex31_2.htm EX-31.2 18931
4 EX-32.1 fdmt-ex32_1.htm EX-32.1 11881
  Complete submission text file 0000950170-24-056933.txt   9675241

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fdmt-20240331.xsd EX-101.SCH 1434928
92 EXTRACTED XBRL INSTANCE DOCUMENT fdmt-20240331_htm.xml XML 1621840
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

IRS No.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39782 | Film No.: 24930604
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)